The promise of cancer immunotherapy and in particular checkpoint inhibitors that target the PD1 PDL1 signaling pathway is the topic of this episode.

We hear about the latest data presented at the 2015 annual meeting of the American Association for Cancer Research (AACR) in Philadelphia.

Interviews with Dr Julie Brahmer (Johns Hopkins), Dr Leisha Emens (Johns Hopkins) and Dr Ira Mellman (Genentech) take us on a journey that highlights some of the challenges and opportunities.

Dr Leisha Emens Johns Hopkins

We also hear from Dr Suzanne Topalian (Johns Hopkins), Dr Antoni Ribas (UCLA) and Dr Pasi Jänne (Dana-Farber Cancer Institute).

Lung cancer is the leading cause of cancer death in the United States.

Dr Roy HerbstPersonalized Immunotherapy for Non-Small Cell Lung Cancer was the title of an outstanding presentation by Roy Herbst MD PhD, at last year’s annual meeting of the Society for Immunotherapy of Cancer (SITC).

Following his talk, Dr Herbst kindly shared his thoughts on lung cancer immunotherapy, and his experience of participating in clinical trials of checkpoint inhibitors that target the PD-1 (and it’s ligand PD-L1) cell signaling pathway.

This is the third prologue that “sets the scene” in cancer immunotherapy prior to the launch of the first episode of Novel Targets in a few weeks time.